Therapeutics News and Research

RSS

Skin cancer researchers throw new light on tumour growth

Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.

14 Jul 2009

Researchers profile genes in acutely ill idiopathic pulmonary fibrosis patients

The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.

7 Jul 2009

Specialized glycans act as tumor suppressors

Scientists at Burnham Institute for Medical Research (Burnham) have discovered that specialized complex sugar molecules (glycans) that anchor cells into place act as tumor suppressors in breast and prostate cancers.

6 Jul 2009

Computer-guided nanoparticle therapy destroys tumors

Gold nanoshells are among the most promising new nanoscale therapeutics being developed to kill tumors, acting as antennas that turn light energy into heat that cooks cancer to death. Now, a multi-institutional research team has shown that polymer-coated gold nanorods one-up their spherical counterparts, with a single dose completely destroying all tumors in a nonhuman animal model of human cancer.

28 Jun 2009

New tuberculosis drug targets

A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis.

23 Jun 2009

Goby fish may bring new drugs for high blood pressure

Medical scientists at the University of Leicester are investigating how a species of fish from the Pacific Ocean could help provide answers to tackling chronic conditions such as hereditary high blood pressure and kidney disease.

22 Jun 2009

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Circadian Technologies granted significant European patent

Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.

17 Jun 2009

Discovery in dendritic cell signalling pathways pave way for new therapeutic targets

Scientists from A*STAR's Singapore Immunology Network (SIgN) and the University of Milano-Bicocca, Italy, have discovered another signaling pathway for the activation and apoptosis, or programmed cell death, of dendritic cells. This discovery was published in the advanced online publication of Nature on 15 Jun 2009.

15 Jun 2009

Scientists gain new insights into the genetic susceptibility of multiple sclerosis

Australian and New Zealand researchers have accelerated research into Multiple Sclerosis by discovering two new locations of genes which will help to unravel the causes of MS and other autoimmune disease.

15 Jun 2009

Single gene found to control growth of some cancers

Research led by Ashok Aiyar, PhD, Associate Professor of Microbiology at LSU Health Sciences Center New Orleans, showing that a single gene can control growth in cancers related to the Epstein-Barr virus and that existing therapeutics can inactivate it, will be published in the June 12, 2009 online issue of PLoS Pathogens.

15 Jun 2009

Innovative partnership targets cancer-causing 'chaperones'

Cancer Research Technology (CRT) and The Institute of Cancer Research (ICR) today announced a major research collaboration with AstraZeneca. The three partners will combine their expertise to discover and develop potential new anti-cancer drugs to target molecular "chaperones" which support the growth of cancer cells.

10 Jun 2009

New understanding of structure of bacteria responsible for traveler's diarrhea

Researchers at Boston University School of Medicine (BUSM), the Naval Medical Research Center and the National Institutes of Health, have solved the structure of thin hair-like fibers called "pili" or "fimbriae" on the surface of bacteria that cause traveler's diarrhea.

9 Jun 2009

New lung cancer therapy with vaporized viral vector shows promise

A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.

9 Jun 2009

Development of innovative nanotechnology drug delivery system for the treatment of pain

Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain.

25 May 2009

Researchers discuss combined approach to maximize benefits and minimize risks of stem cell therapy

Once placed into a patient's body, stem cells intended to treat or cure a disease could end up wreaking havoc simply because they are no longer under the control of the clinician.

22 May 2009

NIH to develop therapeutics for rare and neglected diseases

The National Institutes of Health is launching the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

20 May 2009

Resverlogix files two patents on compounds for inflammatory diseases

Resverlogix Corp. has announced today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases.

19 May 2009

Aerosol delivery of antibiotics via nanoparticles

Aerosol delivery of antibiotics via nanoparticles may provide a means to improve drug delivery and increase patient compliance, thus reducing the severity of individual illnesses, the spread of epidemics, and possibly even retarding antibiotic resistance.

19 May 2009

Intradigm issued RNA interference (RNAi) patent covering potent siRNA sequence

Intradigm Corporation has announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases."

19 May 2009